Humanized antibodies and compositions for binding sphingosine-1-phosphate
View Patent ↗The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
1. An isolated humanized antibody, or an antigen binding fragment thereof, that binds sphingosine-1-phosphate (S1P) and comprising at least one heavy chain variable domain and at least one light chain variable domain, wherein:
A. each heavy chain variable domain comprises:
(i) a first sequence of amino acid residues of sequence DHTIH (SEQ ID NO: 13);
(ii) a second sequence of amino acid residues AISPRHDITKYNEMFRG (SEQ ID NO: 31); and
(iii) a third sequence of amino acid residues of sequence GGFYGSTIWFDF (SEQ ID NO: 15); and
B. each light chain variable domain comprises:
(i) a first sequence of amino acid residues of sequence ITTTDIDDDMN (SEQ ID NO: 10);
(ii) a second sequence of amino acid residues of sequence EGNILRP (SEQ ID NO: 11); and
(iii) a third sequence of amino acid residues of sequence LQSDNLPFT SEQ ID NO: 12).
2. An isolated humanized antibody, or an antigen binding fragment thereof, according to claim 1 , wherein:
A. each heavy chain variable domain comprises a sequence of amino acid residues having an amino acid sequence
(SEQ ID NO: 32, residues 20-140, inclusive)
EVQLVQSGAEVKKPGESLKISCQSFGYIFIDHTIHWMRQMPGQGLEWM
GAISPRHDITKYNEMFRGQVTISADKSSSTAYLQWSSLKASDTAMYFCA
RGGFYGSTIWFDFWGQGTMVTVSS;
and
B. each light chain variable domain comprises a sequence of amino acid residues having an amino acid sequence
(SEQ ID NO: 33, residues 21-127, inclusive)
ETTVTQSPSFLSASVGDRVTITCITTTDIDDDMNWFQQEPG
KAPKLLISEGNILRPGVPSRFSSSGYGTDFTLTISKLQPEDF
ATYYCLQSDNLPFTFGQGTKLEIK.
3. An isolated humanized antibody according to claim 1 , wherein:
A. at least one heavy chain comprises a sequence of amino acid residues having an amino acid sequence:
(SEQ ID NO: 38, residues 20-455, inclusive)
EVQLVQSGAEVKKPGESLKISCQSFGYIFIDHTIHWMRQMPGQGLE
WMGAISPRHDITKYNEMFRGQVTISADKSSSTAYLQWSSLKASDTAMY
FCARGGFYGSTIWFDFWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEL
LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE
WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK;
and
B. at least one light chain comprises a sequence of amino acid residues having an amino acid sequence:
(SEQ ID NO: 37, residues 21-234, inclusive)
ETTVTQSPSFLSASVGDRVTITCITTTDIDDDMNWFQQEPGKAPKL
LISEGNILRPGVPSRFSSSGYGTDFTLTISKLQPEDFATYYCLQSDNLPF
TFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC.
4. An isolated humanized antibody according to claim 1 , wherein:
A. each heavy chain comprises a sequence of amino acid residues having an amino acid sequence:
(SEQ ID NO: 38, residues 20-455, inclusive)
EVQLVQSGAEVKKPGESLKISCQSFGYIFIDHTIHWMRQMPGQGLE
WMGAISPRHDITKYNEMFRGQVTISADKSSSTAYLQWSSLKASDTAMY
FCARGGFYGSTIWFDFWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEL
LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE
WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPG;
and
B. each light chain comprises a sequence of amino acid residues having an amino acid sequence:
(SEQ ID NO: 37, residues 21-234, inclusive)
ETTVTQSPSFLSASVGDRVTITCITTTDIDDDMNWFQQEPGKAPKL
LISEGNILRPGVPSRFSSSGYGTDFTLTISKLQPEDFATYYCLQSDNLPF
TFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC.
5. An isolated humanized antibody, or an antigen binding fragment thereof, according to claim 1 , wherein:
A. each heavy chain variable domain comprises the same heavy chain variable domain amino acid sequence as the heavy chain variable domain of the antibody that binds S1P encoded by the heavy chain structural gene in vector pATH1009 in ATCC Accession No. PTA-8421; and
B. each light chain variable domain comprises the same light chain variable domain amino acid sequence as the light chain variable domain of the antibody that binds S1P encoded by the light chain structural gene in vector pATH1009 in ATCC Accession No. PTA-8421.
6. An isolated humanized antibody, or an antigen binding fragment thereof, according to claim 1 wherein at least one amino acid residue of the antibody or antigen binding fragment is glycosylated.
7. An isolated humanized antibody according to claim 1 .
8. An isolated humanized antibody according to claim 1 that comprises two heavy chains and two light chains.
9. An isolated humanized antibody according to claim 1 , obtainable from CHO cell line LH1 275, as deposited under accession number ATCC PTA-8422.
10. An isolated humanized antibody according to claim 1 as produced in mammalian cells transfected with the plasmid pATH1009 obtainable from E. coli StB12, as deposited under accession number ATCC PTA-8421.
11. An isolated humanized antibody, or an antigen binding fragment thereof, according to claim 1 , wherein:
A. each heavy chain variable domain comprises the same heavy chain variable domain amino acid sequence as the heavy chain variable domain of the antibody expressed by CHO cell line LH1 275, as deposited under accession number ATCC PTA-8422; and
B. each light chain variable domain comprises the same light chain variable domain amino acid sequence as the light chain variable domain of the antibody expressed by CHO cell line LH1 275, as deposited under accession number ATCC PTA-8422.
12. A pharmaceutical composition comprising an isolated humanized antibody, or an antigen binding fragment thereof, according to claim 1 and a pharmaceutically acceptable carrier.